US Stock MarketDetailed Quotes

IMMP Immutep

Watchlist
  • 2.010
  • +0.010+0.50%
Close Jan 10 16:00 ET
  • 2.010
  • 0.0000.00%
Post 20:01 ET
292.37MMarket Cap-9.10P/E (TTM)

About Immutep Company

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. Its products include eftilagimod alpha (IMP321), IMP761, leramilimab (IMP701), and GSK‘781 (IMP731). The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Company Profile

SymbolIMMP
Company NameImmutep
Listing DateApr 16, 2012
Founded1987
CEOMr. Marc Voigt
MarketNASDAQ
Employees44
Securities TypeDR
ADS Ratio1.0 : 10.0
Fiscal Year Ends06-30
AddressAustralia Square,264 George Street,Level 32, Suite 32.07
CitySydney
ProvinceNew South Wales (NSW)
CountryAustralia
Zip Code2000
Phone61-2-8315-7003
Websitehttp://www.immutep.com

Company Executives

  • Name
  • Position
  • Salary
  • Marc Voigt
  • Director, Chief Executive Officer and Chief Financial Officer
  • 1.06M
  • Deanne Miller
  • Chief Operating Officer, General Counsel and Company Secretary
  • 565.23K
  • Dr. Florian Vogl, M.D.,PhD
  • Chief Medical Officer
  • 955.82K
  • Professor Dr. Frederic Triebel, M.D.
  • Executive Director and Chief Scientific Officer
  • 864.44K
  • Pete A. Meyers
  • Deputy Chairman of the Board
  • 138.71K
  • Dr. Russell J. Howard, PhD
  • Chairman of the Board
  • 222.02K
  • Lis Boyce
  • Independent Director
  • 144.76K
Heat List
US
Overall
Symbol
Price
% Chg

No Data